Perfuze

Key People

• Wayne Allen - CEO
• Liam Mullins - Chief Technology Officer

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: Experienced leadership with prior successful ventures in MedTech.

Perfuze's founders, Wayne Allen and Liam Mullins, previously established Embo Medical, which was acquired by C.R. Bard. Their extensive experience in the MedTech sector positions the company favorably for success.

Clinical Need

Aspect: Very Strong
Summary: Acute ischemic stroke is a leading cause of death and disability.

Stroke affects millions globally, with acute ischemic stroke accounting for approximately 87% of all strokes. Effective treatment solutions are in high demand to reduce mortality and morbidity rates.

Competition

Aspect: Very crowded + Strategics
Summary: Market includes major players like Medtronic, Stryker, and Johnson & Johnson.

The neurovascular devices market is dominated by established companies with extensive resources and distribution networks, making it challenging for new entrants to gain significant market share.

Technical Challenge

Aspect: Predictable
Summary: Development of catheter-based aspiration technology is complex but manageable.

While developing advanced neurovascular catheters involves significant technical expertise, the predictable nature of the challenges allows for effective planning and execution.

Patent

Aspect: Strong
Summary: Perfuze has secured patents for its innovative catheter designs.

Holding patents for unique catheter technologies enhances Perfuze's market position and protects against competitors replicating their designs.

Financing

Aspect: Well-funded
Summary: Raised approximately $23.94 million in Series A funding.

The substantial Series A funding enables Perfuze to advance its product pipeline, conduct clinical trials, and pursue regulatory approvals, positioning the company for growth.

Regulatory

Aspect: 510k/PMA
Summary: Received FDA 510(k) clearance for multiple devices.

Achieving FDA 510(k) clearance for devices like the Millipede 070 Aspiration Catheter demonstrates compliance with regulatory standards, allowing for commercialization in the U.S. market.

Opportunity Rollup

Odds of Success

3.9

Peak Market Share

5.2

Segment CAGR

6.1%

Market Segment

Neurovascular Devices

Market Sub Segment

Neurothrombectomy Devices

Key Takeaway

Perfuze, with its experienced leadership and innovative catheter technology, is well-positioned to address the critical need for effective acute ischemic stroke treatments, despite facing a competitive market landscape.